Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
Karolyi et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.870493
https://c19early.org/karolyi.html